Peripheral artery disease and chronic kidney disease: Clinical synergy to improve outcomes

Advances in Chronic Kidney Disease

Volumn 21, Issue 6, 2014, Pages 460-471

  Garimella, Pranav S ^a,b   Hirsch, Alan T ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Clinical outcomes; Collaborative care; Kidney disease; Multidisciplinary teams; Peripheral artery disease

Indexed keywords

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; HEALTH CARE POLICY; HUMAN; MORBIDITY; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SMOKING CESSATION; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME; ARM; COMORBIDITY; COMPLICATION; INTERMITTENT CLAUDICATION; ISCHEMIA; LEG; MYOCARDIAL INFARCTION; PATIENT CARE; PERIPHERAL ARTERIAL DISEASE; RENAL INSUFFICIENCY, CHRONIC; STROKE; VASCULARIZATION;

COMORBIDITY; HUMANS; INTERMITTENT CLAUDICATION; ISCHEMIA; LOWER EXTREMITY; MYOCARDIAL INFARCTION; PATIENT CARE TEAM; PERIPHERAL ARTERIAL DISEASE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SECONDARY PREVENTION; STROKE; UPPER EXTREMITY;

EID: 84927636509     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2014.07.005     Document Type: Review

References (91)

1. Foley R.N., Murray A.M., Li S., et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005, 16(2):489-495.
2. Keith D.S., Nichols G.A., Gullion C.M., Brown J.B., Smith D.H. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004, 164(6):659-663.
3. Sarnak M.J., Levey A.S., Schoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003, 42(5):1050-1065.
4. O'Hare A.M., Glidden D.V., Fox C.S., Hsu C.Y. High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999-2000. Circulation 2004, 109(3):320-323.
5. Liew Y.P., Bartholomew J.R., Demirjian S., Michaels J., Schreiber M.J. Combined effect of chronic kidney disease and peripheral arterial disease on all-cause mortality in a high-risk population. Clin J Am Soc Nephrol 2008, 3(4):1084-1089.
6. O'Hare A.M., Feinglass J., Sidawy A.N., et al. Impact of renal insufficiency on short-term morbidity and mortality after lower extremity revascularization: data from the Department of Veterans Affairs' National Surgical Quality Improvement Program. J Am Soc Nephrol 2003, 14(5):1287-1295.
7. Wattanakit K., Folsom A.R., Selvin E., Coresh J., Hirsch A.T., Weatherley B.D. Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol 2007, 18(2):629-636.
8. McDermott M.M., Ades P., Guralnik J.M., et al. Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial. JAMA 2009, 301(2):165-174.
9. Fowkes F.G., Rudan D., Rudan I., et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013, 382(9901):1329-1340.
10. Selvin E., Erlinger T.P. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004, 110(6):738-743.
11. Lash J.P., Go A.S., Appel L.J., et al. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol 2009, 4(8):1302-1311.
12. Rooke T.W., Hirsch A.T., Misra S., et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2011, 58(19):2020-2045.
13. Cheung A.K., Sarnak M.J., Yan G., et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000, 58(1):353-362.
14. Rajagopalan S., Dellegrottaglie S., Furniss A.L., et al. Peripheral arterial disease in patients with end-stage renal disease: observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Circulation 2006, 114(18):1914-1922.
15. Fishbane S., Youn S., Flaster E., Adam G., Maesaka J.K. Ankle-arm blood pressure index as a predictor of mortality in hemodialysis patients. Am J Kidney Dis 1996, 27(5):668-672.
16. Testa A., Ottavioli J.N. Arch Mal Coeur Vaiss 1998, 91(8):963-965.
17. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2010, US Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
18. Jaar B.G., Plantinga L.C., Astor B.C., et al. Novel and traditional cardiovascular risk factors for peripheral arterial disease in incident-dialysis patients. Adv Chron Kidney Dis 2007, 14(3):304-313.
19. Chen J., Mohler E.R., Xie D., et al. Risk factors for peripheral arterial disease among patients with chronic kidney disease. Am J Cardiol 2012, 110(1):136-141.
20. Selvin E., Kottgen A., Coresh J. Kidney function estimated from serum creatinine and cystatin C and peripheral arterial disease in NHANES 1999-2002. Eur Heart J 2009, 30(15):1918-1925.
21. Wattanakit K., Folsom A.R., Criqui M.H., et al. Albuminuria and peripheral arterial disease: results from the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis 2008, 201(1):212-216.
22. Wu C.K., Yang C.Y., Tsai C.T., et al. Association of low glomerular filtration rate and albuminuria with peripheral arterial disease: the National Health and Nutrition Examination Survey, 1999-2004. Atherosclerosis 2009, 209(1):230-234.
23. Barzilay J.I., Peterson D., Cushman M., et al. The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: the cardiovascular health study. Am J Kidney Dis 2004, 44(1):25-34.
24. Aboyans V., Ho E., Denenberg J.O., Ho L.A., Natarajan L., Criqui M.H. The association between elevated ankle systolic pressures and peripheral occlusive arterial disease in diabetic and nondiabetic subjects. J Vasc Surg 2008, 48(5):1197-1203.
25. Cooper B.A., Penne E.L., Bartlett L.H., Pollock C.A. Protein malnutrition and hypoalbuminemia as predictors of vascular events and mortality in ESRD. Am J Kidney Dis 2004, 43(1):61-66.
26. Boaz M., Weinstein T., Matas Z., Green, Smetana S. Peripheral vascular disease and serum phosphorus in hemodialysis: a nested case-control study. Clin Nephrol 2005, 63(2):98-105.
27. Melamed M.L., Muntner P., Michos E.D., et al. Serum 25-hydroxy vitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004. Arterioscler Thromb Vasc Biol 2008, 28(6):1179-1185.
28. de Vinuesa S.G., Ortega M., Martinez P., Goicoechea M., Campdera F.G., Luno J. Subclinical peripheral arterial disease in patients with chronic kidney disease: prevalence and related risk factors. Kidney Int Suppl 2005, (93):S44-S47.
29. Manns B.J., Burgess E.D., Hyndman M.E., Parsons H.G., Schaefer J.P., Scott-Douglas N.W. Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am J Kidney Dis 1999, 34(4):669-677.
30. Moyer V.A. Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013, 159(5):342-348.
31. Rooke T.W., Hirsch A.T., Misra S., et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011, 124(18):2020-2045.
32. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005, 45(4 suppl 3):S1-S153.
33. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl 2012, 2:337-414.
34. McDermott M.M., Greenland P., Liu K., et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA 2001, 286(13):1599-1606.
35. Khan N.A., Rahim S.A., Anand S.S., Simel D.L., Panju A. Does the clinical examination predict lower extremity peripheral arterial disease?. JAMA 2006, 295(5):536-546.
36. Hirsch A.T., Haskal Z.J., Hertzer N.R., et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to develop guidelines for the management of patients with peripheral arterial disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; Transatlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006, 113(11):e463-e654.
37. Fowkes F.G., Murray G.D., Butcher I., et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008, 300(2):197-208.
38. O'Hare A.M., Katz R., Shlipak M.G., Cushman M., Newman A.B. Mortality and cardiovascular risk across the ankle-arm index spectrum: results from the Cardiovascular Health Study. Circulation 2006, 113(3):388-393.
39. Leskinen Y., Salenius J.P., Lehtimaki T., Huhtala H., Saha H. The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: requirements for diagnostics. Am J Kidney Dis 2002, 40(3):472-479.
40. Ogata H., Kumata-Maeta C., Shishido K., et al. Detection of peripheral artery disease by duplex ultrasonography among hemodialysis patients. Clin J Am Soc Nephrol 2010, 5(12):2199-2206.
41. Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., Fowkes F.G. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007, 45(suppl S):S5-S67.
42. Suominen V., Uurto I., Saarinen J., Venermo M., Salenius J. PAD as a risk factor for mortality among patients with elevated ABI-a clinical study. Eur J Vasc Endovasc Surg 2010, 39(3):316-322.
43. Hoyer C., Sandermann J., Petersen L.J. The toe-brachial index in the diagnosis of peripheral arterial disease. J Vasc Surg 2013, 58(1):231-238.
44. de Liefde I.I., Klein J., Bax J.J., Verhagen H.J., van Domburg R.T., Poldermans D. Exercise ankle brachial index adds important prognostic information on long-term out-come only in patients with a normal resting ankle brachial index. Atherosclerosis 2011, 216(2):365-369.
45. Koelemay M.J., Lijmer J.G., Stoker J., Legemate D.A., Bossuyt P.M. Magnetic resonance angiography for the evaluation of lower extremity arterial disease: a meta-analysis. JAMA 2001, 285(10):1338-1345.
46. Met R., Bipat S., Legemate D.A., Reekers J.A., Koelemay M.J. Diagnostic performance of computed tomography angiography in peripheral arterial disease: a systematic review and meta-analysis. JAMA 2009, 301(4):415-424.
47. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007, 45(4):645-654. discussion 653-654.
48. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996, 348(9038):1329-1339.
49. Murphy T.P., Cutlip D.E., Regensteiner J.G., et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) Study. Circulation 2012, 125(1):130-139.
50. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324(7329):71-86.
51. Best P.J., Steinhubl S.R., Berger P.B., et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events during Observation (CREDO) trial. Am Heart J 2008, 155(4):687-693.
52. Angiolillo D.J., Bernardo E., Capodanno D., et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 2010, 55(11):1139-1146.
53. A study comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease (EUCLID). Available at:. Accessed April 7,2014. http://clinicaltrials.gov/show/NCT01732822.
54. Bonaca M.P., Scirica B.M., Creager M.A., et al. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation 2013, 127(14):1522-1529. 1529e1-1529e6.
55. Anand S., Yusuf S., Xie C., et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007, 357(3):217-227.
56. National Guideline C. KDIGO 2012 clinical practice guideline for theevaluation and management of chronic kidney disease. Available at:. Accessed January 31,2014. http://www.guideline.gov/content.aspx?id=46510.
57. Hennrikus D., Joseph A.M., Lando H.A., et al. Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial. J Am Coll Cardiol 2010, 56(25):2105-2112.
58. Jonason T., Bergstrom R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand 1987, 221(3):253-260.
59. Bartholomew J.R., Olin J.W. Pathophysiology of peripheral arterial disease and risk factors for its development. Cleve Clin J Med 2006, 73(suppl 4):S8-S14.
60. Foley R.N., Herzog C.A., Collins A.J. Smoking and cardiovascular outcomes in dialysis patients: the United States renal data system Wave 2 study. Kidney Int 2003, 63(4):1462-1467.
61. Selvin E., Wattanakit K., Steffes M.W., Coresh J., Sharrett A.R. HbA1c and peripheral arterial disease in diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 2006, 29(4):877-882.
62. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352(9131):837-853.
63. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 2012, 60(5):850-886.
64. Jafar T.H., Schmid C.H., Landa M., et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001, 135(2):73-87.
65. Espinola-Klein C., Weisser G., Jagodzinski A., et al. {beta}-Blockers in patients with intermittent claudication and arterial hypertension: results from the Nebivolol or Metoprolol in arterial occlusive disease trial. Hypertension 2011, 58(2):148-154.
66. Mohler E.R., Hiatt W.R., Creager M.A. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003, 108(12):1481-1486.
67. Fellstrom B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360(14):1395-1407.
68. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J 2010, 160(5):785-794.e10. Sharp Collaborative G.
69. Stewart K.J., Hiatt W.R., Regensteiner J.G., Hirsch A.T. Exercise training for claudication. N Engl J Med 2002, 347(24):1941-1951.
70. McDermott M.M., Liu K., Ferrucci L., et al. Physical performance in peripheral arterial disease: a slower rate of decline in patients who walk more. Ann Intern Med 2006, 144(1):10-20.
71. McDermott M.M., Liu K., Guralnik J.M., et al. Home-based walking exercise intervention in peripheral artery disease: a randomized clinical trial. JAMA 2013, 310(1):57-65.
72. Robless P., Mikhailidis D.P., Stansby G.P. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev 2008, (1):CD003748.
73. O'Hare A.M., Bertenthal D., Sidawy A.N., Shlipak M.G., Sen S., Chren M.M. Renal insufficiency and use of revascularization among a national cohort of men with advanced lower extremity peripheral arterial disease. Clin J Am Soc Nephrol 2006, 1(2):297-304.
74. Ortmann J., Gahl B., Diehm N., Dick F., Traupe T., Baumgartner I. Survival benefits of revascularization in patients with critical limb ischemia and renal insufficiency. J Vasc Surg 2012, 56(3):737-745.e1.
75. Casserly I.P. Interventional management of critical limb ischemia in renal patients. Adv Chron Kidney Dis 2008, 15(4):384-395.
76. Kumada Y., Aoyama T., Ishii H., et al. Long-term outcome of percutaneous transluminal angioplasty in chronic haemodialysis patients with peripheral arterial disease. Nephrol Dial Transplant 2008, 23(12):3996-4001.
77. Graziani L., Silvestro A., Bertone V., et al. Percutaneous transluminal angioplasty is feasible and effective in patients on chronic dialysis with severe peripheral artery disease. Nephrol Dial Transplant 2007, 22(4):1144-1149.
78. Adam D.J., Beard J.D., Cleveland T., et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL): multicentre, randomised controlled trial. Lancet 2005, 366(9501):1925-1934.
79. Bradbury A.W., Adam D.J., Bell J., et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: an intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy. J Vasc Surg 2010, 51(5 suppl):5S-17S.
80. Albers M., Romiti M., De Luccia N., Brochado-Neto F.C., Nishimoto I., Pereira C.A. An updated meta-analysis of infrainguinal arterial reconstruction in patients with end-stage renal disease. J Vasc Surg 2007, 45(3):536-542.
81. Reddan D.N., Marcus R.J., Owen W.F., Szczech L.A., Landwehr D.M. Long-term outcomes of revascularization for peripheral vascular disease in end-stage renal disease patients. Am J Kidney Dis 2001, 38(1):57-63.
82. Eggers P.W., Gohdes D., Pugh J. Nontraumatic lower extremity amputations in the Medicare end-stage renal disease population. Kidney Int 1999, 56(4):1524-1533.
83. O'Hare A.M., Feinglass J., Reiber G.E., et al. Postoperative mortality after nontraumatic lower extremity amputation in patients with renal insufficiency. J Am Soc Nephrol 2004, 15(2):427-434.
84. Dachun X., Jue L., Liling Z., et al. Sensitivity and specificity of the ankle-brachial index to diagnose peripheral artery disease: a structured review. Vasc Med 2010, 15(5):361-369.
85. Doherty R.B., Crowley R.A. Principles supporting dynamic clinical care teams: an American College of Physicians position paper. Ann Intern Med 2013, 159(9):620-626.
86. Layden J., Michaels J., Bermingham S., Higgins B. Diagnosis and management of lower limb peripheral arterial disease: summary of NICE guidance. BMJ 2012, 345:e4947.
87. Lipscombe J., Jassal S.V., Bailey S., Bargman J.M., Vas S., Oreopoulos D.G. Chiropody may prevent amputations in diabetic patients on peritoneal dialysis. Perit Dial Int 2003, 23(3):255-259.
88. McMurray S.D., Johnson G., Davis S., McDougall K. Diabetes education and care management significantly improve patient outcomes in the dialysis unit. Am J Kidney Dis 2002, 40(3):566-575.
89. The Comprehensive End Stage Renal Disease Care Model (CEC). Available at:. Accessed March 26,2013. http://www.impaqint.com/public-comment-comprehensive-esrd-care-cec-measure-set.
90. Dumaine R.L., Montalescot G., Steg P.G., Ohman E.M., Eagle K., Bhatt D.L. Renal function, atherothrombosis extent, and outcomes in high-risk patients. Am Heart J 2009, 158(1):141-148.e1.
91. Dean P.G., Lund W.J., Larson T.S., et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004, 77(10):1555-1561.